Navigation Links
New England Biolabs Expands its Distribution Network through Collaborations in India and the Netherlands
Date:4/12/2011

IPSWICH, Mass., April 12, 2011 /PRNewswire/ -- New England Biolabs (NEB), a world leader in the production and supply of reagents for life science research, announces that it has signed exclusive distribution agreements with BIOKE, based in the Netherlands, and Imperial Life Sciences (ILS), based in India.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b)

BIOKE, a Cell Signaling Technology (CST) Europe BV company, is located in Leiden, the Netherlands, and serves Belgium, the Netherlands and Luxemborg. BIOKE supplies reagents for signal transduction, cell culture, molecular biology and laboratory equipment. ILS is a biosupplier company based in Gurgaon, India that currently supplies reagents and instrumentation for genomics, proteomics, cell biology and imaging. By signing agreements in these two regions, NEB's distribution network now extends to 39 companies worldwide.

"NEB maintains an extensive global distribution network to afford our customers efficient access to our high quality reagents throughout the world," states Dr. Peter Nathan, Director of Global Business Development at NEB. "Collaborations with companies such as BIOKE and ILS further strengthen our ability to support the needs of our customers, through their service capabilities, including both ease-of-procurement and excellent technical support."

About NEB

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications, and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs, visit www.neb.com.


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. River Valley Community College and Medical Messenger Team Up to Prepare the Future Nurses of New England
2. Technology Collaboration Between New England Biolabs and Sequenom Delivers First Product for Epigenetics
3. Hospitalists at New England Baptist Hospital Choose MedAptus
4. New England Biolabs Releases JoVE Video Protocol Highlighting Assay to Quantitate 5-hmC in Epigenome
5. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
6. Pescatello Elected to Head New England Biotech Association in 2011-12
7. Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine
8. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
9. Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
10. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
11. New England Biolabs Receives Award to Develop Novel Enzymatic Reagents for Epigenetic Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... India , December 5, 2016 According ... by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free ... published by MarketsandMarkets, the market is projected to reach USD 779.8 ... a CAGR of 13.5% during the forecast period of 2016 to ... ...
(Date:12/5/2016)... and PUNE, India , December 5, ... by Allied Market Research, titled, "Global Cancer Biomarkers Market - ... of cancer biomarkers market is projected to reach $15,737 million ... of 13.3% from 2016 to 2022. Omic technologies segment accounted ... and is expected to maintain its dominance during the forecast ...
(Date:12/5/2016)...  CVS Health, the nation,s largest pharmacy innovation company, ... of 100 percent on the Corporate Equality Index (CEI) ... annual national benchmarking survey and report on corporate policies ... Human Rights Campaign Foundation. "Our company,s ... customers and suppliers bring to CVS Health," said ...
Breaking Medicine Technology:
(Date:12/5/2016)... Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... concussions have on the growing brains of young athletes. Over the course of three ... the head through unique mouth guards. The mouth guards, equipped with special sensors, will ...
(Date:12/5/2016)... NY (PRWEB) , ... December 05, 2016 , ... ... to use a patent-pending blend of L-Citrulline and glutathione to enhance production of ... a combination that studies have shown to produce NO twice as effectively and ...
(Date:12/5/2016)... ... December 05, 2016 , ... Eating disorders ... goal of Castlewood Treatment Centers has always been to promote the power of ... people as possible. In that spirit, Castlewood has announced two new hires, both ...
(Date:12/5/2016)... ... December 05, 2016 , ... U.S. Apple Association (USApple) ... part of the second annual Apples for Education: Buy an Apple, Help a ... providing healthy food for students to take home to their families; solar technology to ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Partners ("GPP") portfolio company, today announced it has acquired the assets of ... was previously a subsidiary of Chiltern International and focuses on clinical trial ...
Breaking Medicine News(10 mins):